DrugPatentWatch Database Preview
Drugs in Development Information for GLPG2737
» See Plans and Pricing
What is the drug development status for GLPG2737?
GLPG2737 is an investigational drug.
There have been 5 clinical trials for GLPG2737.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 29th 2017.
The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Polycystic Kidney, Autosomal Dominant. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].
There are two US patents protecting this investigational drug and seventeen international patents.
Summary for GLPG2737
| US Patents | 2 |
| International Patents | 17 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-11-29) |
| Vendors | 0 |
Recent Clinical Trials for GLPG2737
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Galapagos NV | Phase 2 |
| A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. | Galapagos NV | Phase 1 |
| GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis | Galapagos NV | Phase 2 |
Clinical Trial Summary for GLPG2737
Top disease conditions for GLPG2737
Top clinical trial sponsors for GLPG2737
US Patents for GLPG2737
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GLPG2737 | Start Trial | Compounds, compositions, and methods for modulating CFTR | Proteostasis Therapeutics, Inc. (Boston, MA) | Start Trial |
| GLPG2737 | Start Trial | Compounds, compositions, and methods for increasing CFTR activity | Proteostasis Therapeutics, Inc. (Boston, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GLPG2737
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GLPG2737 | Argentina | AR108203 | 2036-04-07 | Start Trial |
| GLPG2737 | Australia | AU2017248253 | 2036-04-07 | Start Trial |
| GLPG2737 | Brazil | BR112018070747 | 2036-04-07 | Start Trial |
| GLPG2737 | Canada | CA3019663 | 2036-04-07 | Start Trial |
| GLPG2737 | China | CN109563047 | 2036-04-07 | Start Trial |
| GLPG2737 | European Patent Office | EP3440057 | 2036-04-07 | Start Trial |
| GLPG2737 | Israel | IL262030 | 2036-04-07 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
